Effects of Rifaximin on Gut Microbiota and Emotion

Exclusion Criteria18

• Participant has a history of previous or current neurological, psychiatric, gastrointestinal or endocrine disorder
• Any disorder, which in the Investigator's opinion might jeopardize the participant's safety or compliance with the protocol
• Any prior or concomitant treatment(s) that might jeopardize the participant's safety or that would compromise the integrity of the Trial
• Participation in an interventional Trial with an investigational medicinal product (IMP) or device
• Hypersensitivity to the active substance rifaximin, to any rifamycin (e.g. rifampicin or rifabutin) or any of the excipients
• Current or recent medication use
• Use of antibiotics within three months preceding the study
• Current or recent (1-month) infection (e.g. common cold, influenza, COVID-19, etc.)
• Previous or current substance/alcohol dependence or abuse (>2 units per day or 14 units per week)
• One or more diagnoses based on the mini international neuropsychiatric interview (MINI-S)
• One or more diagnoses based on ROME IV for gastrointestinal disorders
• Smoking
• Night-shift work
• Adherence to special diets (e.g. vegan, vegetarian, weight-loss, lactose-free, gluten-free, etc.)
• Use of pre- or probiotics within one month preceding the study
• Previous experience with any of the tasks used in the study (not including questionnaires)
• Color vision deficiency (colorblindness)
• Magnetic Resonance Imaging (MRI) contraindications, including claustrophobia, severe back problems, conditions that would interfere with MRI scanning (e.g. cochlear implant, metal fragments in eyes, metallic body inclusion, or other metal implanted in the body), and if the participant does not want to be informed of incidental findings that might be found during imaging.